Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Sidse Vang Braa Andersen; Lisbeth Samsø Schmidt; Ulla Birgitte Hartling; Anne Cathrine F. Viuff; Mette Holm; Lone Graff Stensballe; Marie Louise Von Linstow

doi:10.61409/V11250898

Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Translated title of the contribution: Prevention of respiratory syncytial virus in children

Sidse Vang Braa Andersen
, Lisbeth Samsø Schmidt
, Ulla Birgitte Hartling
, Anne Cathrine F. Viuff
, Mette Holm
, Lone Graff Stensballe
, Marie Louise Von Linstow^*

^*Corresponding author for this work

KI, OUH, Research unit of Paediatrics (Odense)

University of Copenhagen
Herlev Hospital
Aarhus University Hospital
Rigshospitalet

Research output: Contribution to journal › Journal article › Research › peer-review

4 Downloads (Pure)

Abstract

Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

Translated title of the contribution	Prevention of respiratory syncytial virus in children
Original language	Danish
Article number	V11250898
Journal	Ugeskrift for Læger
Volume	188
Issue number	11
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V11250898
Publication status	Published - 25. May 2026

Documents & Links

10.61409/V11250898Licence: CC BY-NC-ND

Open Access VersionFinal published version, 615 KBLicence: CC BY-NC-ND

SDU Link

Check access to the material in SDU Library's search engine

Cite this

@article{10f1ed1efd8f462f9b7de233ba29ba97,

title = "Forebyggelse af respiratorisk syncytialvirus-infektion hos sp{\ae}db{\o}rn",

abstract = "Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.",

author = "\{Braa Andersen\}, \{Sidse Vang\} and Schmidt, \{Lisbeth Sams{\o}\} and Hartling, \{Ulla Birgitte\} and Viuff, \{Anne Cathrine F.\} and Mette Holm and Stensballe, \{Lone Graff\} and \{Von Linstow\}, \{Marie Louise\}",

year = "2026",

month = may,

day = "25",

doi = "10.61409/V11250898",

language = "Dansk",

volume = "188",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "L{\ae}geforeningen",

number = "11",

}

TY - JOUR

T1 - Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

AU - Braa Andersen, Sidse Vang

AU - Schmidt, Lisbeth Samsø

AU - Hartling, Ulla Birgitte

AU - Viuff, Anne Cathrine F.

AU - Holm, Mette

AU - Stensballe, Lone Graff

AU - Von Linstow, Marie Louise

PY - 2026/5/25

Y1 - 2026/5/25

N2 - Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

AB - Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

U2 - 10.61409/V11250898

DO - 10.61409/V11250898

M3 - Tidsskriftartikel

C2 - 41738099

SN - 0041-5782

VL - 188

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 11

M1 - V11250898

ER -

Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Abstract

Documents & Links

SDU Link

Fingerprint

Cite this